8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

MYOMO, INC.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 26, 2024, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Myomo, Inc. (the "Company"), the Board increased its size from six to seven members and appointed Heather Getz to join the Board, effective on March 26, 2024. Ms. Getz will serve as a Class II director until her term expires at the 2025 annual meeting of shareholders, at which time she will stand for election by the Company’s shareholders. Ms. Getz was also appointed to serve as a member and chair of the audit committee of the Board. The Board determined that Ms. Getz is independent under the listing standards of NYSE American and has designated Ms. Getz as an audit committee financial expert as defined under the applicable rules of the Securities and Exchange Commission.

Ms. Getz, 49, is currently executive vice president and chief financial and operations officer of Butterfly Network, Inc ("Butterfly"). a publicly traded medical device company. She has held the role of chief financial officer upon joining Butterfly in May 2022 and operations was added to her responsibilities in July 2023. Ms. Getz has held chief financial officer and other senior executive roles since 2010. Ms. Getz received her undergraduate degree in Accountancy and a Master of Business Administration degree from Villanova University, and is a certified public accountant.

As a non-employee director, Ms. Getz will receive an annual cash retainer of $55,000, which includes an additional $5,000 annually for being a committee chair. The cash retainer is paid quarterly. In addition, Ms. Getz will be entitled to receive $30,000 annually, paid in the form of restricted stock units, which vest over four quarters .Ms. Getz is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Ms. Getz and any other persons pursuant to which she was selected as a director. In addition, Ms. Getz has entered into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

Item 7.01 Regulation FD Disclosures.

On March 28, 2024, the Company issued a press release announcing the appointment of Ms. Getz. A copy of the Company’s press release relating to this announcement is attached as Exhibit 99.1 to this current report on Form 8-K (the “Report”).

The information contained in Item 7.01 of this Report and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1

Exhibit 99.1

Myomo Appoints Heather Getz to its Board of Directors

BOSTON (March 28, 2024) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors

.

Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic planning.

“We welcome Heather to the Myomo board of directors,” said Paul R. Gudonis, chairman and chief executive officer of Myomo. "She brings financial and operational experience in scaling medical device and technology companies, which will be valuable to the board of directors as Myomo accelerates its growth."

Ms. Getz currently holds the position of executive vice president and chief financial and operations officer of Butterfly Network Inc. (NYSE: BFLY), a digital health company that is transforming care with handheld, whole-body ultrasound. For the 12 years prior to Butterfly Network, Ms. Getz was the chief financial and administrative officer of BioTelemetry where she was responsible for all aspects of company financial, investor relations, human relations, legal and compliance functions, and worked extensively in strategic planning. She has also held leadership positions at VIASYS Healthcare, Alita Pharmaceuticals and Healthy.io.

“I am excited to join the Myomo board at such a pivotal time in the company’s history. I am very impressed by the technology and how it has been used to restore function in the paralyzed or weakened arms and hands of individuals that have suffered injury so that they can return to work, live independently and reduce their cost of care,” said Ms. Getz. “I look forward to working with the team to further accelerate the company’s already impressive growth.”

Ms. Getz holds Master of Business Administration and a Bachelor’s degree in accountancy from Villanova University. She is a certified public accountant and a member of the American Institute of Certified Public Accountants (AICPA), the Pennsylvania Institute of CPAs (PICPA), the National Investor Relations Institute (NIRI) and the National Association for Corporate Directors (NACD).

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living,

Myomo Inc. | 137 Portland Street 4th Floor | Boston, MA 02114

TEL: 877.736.9666 www.myomo.com info@myomo.com

including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Contacts:

For Myomo:

ir@myomo.com

Investor Relations:

Kim Sutton Golodetz

LHA Investor Relations

212-838-3777

kgolodetz@lhai.com